You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRidogrel
Accession NumberDB01207  (APRD00271)
TypeSmall Molecule
GroupsApproved
DescriptionRidogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.
Structure
Thumb
Synonyms
R-68070
Ridogrel
Ridogrelum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQTS5QOO42O
CAS number110140-89-1
WeightAverage: 366.3344
Monoisotopic: 366.119127035
Chemical FormulaC18H17F3N2O3
InChI KeyGLLPUTYLZIKEGF-HAVVHWLPSA-N
InChI
InChI=1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+
IUPAC Name
5-{[(E)-{pyridin-3-yl[3-(trifluoromethyl)phenyl]methylidene}amino]oxy}pentanoic acid
SMILES
OC(=O)CCCCO\N=C(\C1=CN=CC=C1)C1=CC(=CC=C1)C(F)(F)F
Pharmacology
IndicationUsed as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction.
Structured Indications Not Available
PharmacodynamicsRidogrel, a combined thromboxane synthase inhibitor and receptor antagonist, is used with streptokinase as an adjunctive therapy to reduce the formation and size of blood clots. Blood clots can cause ischemic cardiac events (heart attacks). Ridogrel has the dual property of inhibiting the synthesis of thromboxane and blocking the receptors of thromboxane/prostaglandin/endoperoxides. It has been shown to accelerate the speed of recanalization and to delay or prevent reocclusion during systemic thrombolysis with tissue plasminogen activator (streptokinase). Ridogrel is a more potent antiplatelet agent than aspirin and might offer an advantage over aspirin as an adjunct to thrombolysis in patients suffering from acute myocardial infarction. While aspirin inhibits cyclooxygenase, the enzyme responsible for producing thromboxane, ridogrel inhibits thromboxane synthesis directly. A recent comparison between aspirin and ridogrel in as adjunct to thrombolysis in patients with acute myocardial infarction demonstrated that ridogrel is not superior to aspirin in enhancing the fibrinolytic efficacy of streptokinase but might be more effective in preventing new ischemic events. Clinical experience with this drug is still relatively limited.
Mechanism of actionRidogrel inhibits thromboxane A2 synthase and also blocks the thromboxane A2/prostaglandin endoperoxide receptors. Thromboxane synthetase produces thromboxane in platelets. Thromboxane is a vasoconstrictor and facilitates the clumping of platelets. Therefore by inhibiting the production and promotion of thromboxane, thrombolysis is enhanced.
TargetKindPharmacological actionActionsOrganismUniProt ID
Thromboxane-A synthaseProteinyes
inhibitor
HumanP24557 details
Thromboxane A2 receptorProteinyes
antagonist
HumanP21731 details
Related Articles
AbsorptionRapidly absorbed after oral administration (30-60 min)
Volume of distributionNot Available
Protein bindingApproximately 60% bound to plasma proteins
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabRidogrel may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolRidogrel may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ridogrel is combined with Acetylsalicylic acid.Approved, Vet Approved
AlprostadilAlprostadil may increase the antiplatelet activities of Ridogrel.Approved, Investigational
AlteplaseRidogrel may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Ridogrel may increase the anticoagulant activities of ALX-0081.Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Ridogrel is combined with Aminosalicylic Acid.Approved
AnagrelideRidogrel may increase the anticoagulant activities of Anagrelide.Approved
AncrodRidogrel may increase the anticoagulant activities of Ancrod.Investigational
AnistreplaseRidogrel may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanRidogrel may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Ridogrel is combined with Apixaban.Approved
ArdeparinRidogrel may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanRidogrel may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinRidogrel may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the antiplatelet activities of Ridogrel.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Ridogrel is combined with Balsalazide.Approved, Investigational
BatroxobinRidogrel may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminRidogrel may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinRidogrel may increase the anticoagulant activities of Bemiparin.Approved
BeraprostRidogrel may increase the anticoagulant activities of Beraprost.Investigational
BivalirudinRidogrel may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
ButylphthalideRidogrel may increase the antiplatelet activities of Butylphthalide.Investigational
CangrelorRidogrel may increase the anticoagulant activities of Cangrelor.Approved
CertoparinRidogrel may increase the anticoagulant activities of Certoparin.Approved
CilostazolRidogrel may increase the anticoagulant activities of Cilostazol.Approved
Citric AcidRidogrel may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClopidogrelRidogrel may increase the anticoagulant activities of Clopidogrel.Approved, Nutraceutical
CollagenaseThe risk or severity of adverse effects can be increased when Ridogrel is combined with Collagenase.Approved
Dabigatran etexilateRidogrel may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinRidogrel may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidRidogrel may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of Ridogrel.Approved, Investigational
DefibrotideRidogrel may increase the anticoagulant activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ridogrel is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Ridogrel is combined with dersalazine.Investigational
DesirudinRidogrel may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseRidogrel may increase the anticoagulant activities of Desmoteplase.Investigational
DextranRidogrel may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Ridogrel may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Ridogrel may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Ridogrel may increase the anticoagulant activities of Dextran 75.Approved
DicoumarolRidogrel may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Ridogrel is combined with Diflunisal.Approved
DipyridamoleRidogrel may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleRidogrel may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaRidogrel may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidRidogrel may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanRidogrel may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinRidogrel may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the antiplatelet activities of Ridogrel.Approved, Investigational
eplivanserineRidogrel may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Ridogrel.Approved
EptifibatideRidogrel may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
Ethyl biscoumacetateRidogrel may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FibrinolysinRidogrel may increase the anticoagulant activities of Fibrinolysin.Approved
FluindioneRidogrel may increase the anticoagulant activities of Fluindione.Investigational
FondaparinuxRidogrel may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumRidogrel may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateRidogrel may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Ridogrel.Approved
HeparinRidogrel may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineRidogrel may increase the anticoagulant activities of Higenamine.Investigational
HirulogRidogrel may increase the anticoagulant activities of Hirulog.Experimental
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ridogrel is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ridogrel.Approved
IbudilastRidogrel may increase the antiplatelet activities of Ibudilast.Approved, Investigational
Icosapent ethylRidogrel may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
idraparinuxRidogrel may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilRidogrel may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloprostIloprost may increase the antiplatelet activities of Ridogrel.Approved, Investigational
IndobufenRidogrel may increase the anticoagulant activities of Indobufen.Investigational
Kct 0809Ridogrel may increase the anticoagulant activities of Kct 0809.Investigational
KetanserinRidogrel may increase the antiplatelet activities of Ketanserin.Investigational
LepirudinRidogrel may increase the anticoagulant activities of Lepirudin.Approved
LimaprostLimaprost may increase the antiplatelet activities of Ridogrel.Approved
MesalazineThe risk or severity of adverse effects can be increased when Ridogrel is combined with Mesalazine.Approved
MilrinoneMilrinone may increase the antiplatelet activities of Ridogrel.Approved
NadroparinRidogrel may increase the anticoagulant activities of Nadroparin.Approved
NafamostatRidogrel may increase the anticoagulant activities of Nafamostat.Investigational
NaftopidilRidogrel may increase the antiplatelet activities of Naftopidil.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Ridogrel is combined with NCX 4016.Investigational
NimesulideRidogrel may increase the antiplatelet activities of Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Ridogrel is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Ridogrel is combined with Obinutuzumab.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Ridogrel is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Ridogrel.Approved
OtamixabanRidogrel may increase the anticoagulant activities of Otamixaban.Investigational
ParnaparinRidogrel may increase the anticoagulant activities of Parnaparin.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ridogrel.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Ridogrel.Approved, Investigational
PhenindioneRidogrel may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonRidogrel may increase the anticoagulant activities of Phenprocoumon.Approved
PlasminRidogrel may increase the anticoagulant activities of Plasmin.Investigational
PrasugrelRidogrel may increase the anticoagulant activities of Prasugrel.Approved
Protein CRidogrel may increase the anticoagulant activities of Protein C.Approved
Protein S humanRidogrel may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeRidogrel may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanRidogrel may increase the antiplatelet activities of Ramatroban.Investigational
ResveratrolRidogrel may increase the antiplatelet activities of Resveratrol.Experimental, Investigational
ReteplaseRidogrel may increase the anticoagulant activities of Reteplase.Approved
ReviparinRidogrel may increase the anticoagulant activities of Reviparin.Approved
RivaroxabanRidogrel may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneRidogrel may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Ridogrel is combined with Salicylic acid.Approved, Vet Approved
SCH-530348Ridogrel may increase the antiplatelet activities of SCH-530348.Investigational
SelexipagRidogrel may increase the anticoagulant activities of Selexipag.Approved
SevofluraneRidogrel may increase the antiplatelet activities of Sevoflurane.Approved, Vet Approved
SRT501Ridogrel may increase the antiplatelet activities of SRT501.Investigational
StreptokinaseRidogrel may increase the anticoagulant activities of Streptokinase.Approved
SulodexideRidogrel may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseRidogrel may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneRidogrel may increase the antiplatelet activities of Tesmilifene.Investigational
TicagrelorRidogrel may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineRidogrel may increase the anticoagulant activities of Ticlopidine.Approved
TinzaparinRidogrel may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Ridogrel.Approved, Investigational
TirofibanRidogrel may increase the anticoagulant activities of Tirofiban.Approved
TositumomabThe risk or severity of adverse effects can be increased when Ridogrel is combined with Tositumomab.Approved
TranilastRidogrel may increase the antiplatelet activities of Tranilast.Approved, Investigational
TrapidilRidogrel may increase the antiplatelet activities of Trapidil.Approved
TreprostinilTreprostinil may increase the antiplatelet activities of Ridogrel.Approved, Investigational
TriflusalRidogrel may increase the anticoagulant activities of Triflusal.Approved
UrokinaseRidogrel may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Ridogrel.Approved, Nutraceutical, Vet Approved
VorapaxarRidogrel may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinRidogrel may increase the anticoagulant activities of Warfarin.Approved
XimelagatranRidogrel may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Ridogrel may increase the anticoagulant activities of Ym150.Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9925
Blood Brain Barrier+0.9613
Caco-2 permeable-0.5694
P-glycoprotein substrateNon-substrate0.5312
P-glycoprotein inhibitor INon-inhibitor0.6419
P-glycoprotein inhibitor IINon-inhibitor0.8893
Renal organic cation transporterNon-inhibitor0.5991
CYP450 2C9 substrateNon-substrate0.8073
CYP450 2D6 substrateNon-substrate0.7912
CYP450 3A4 substrateNon-substrate0.5846
CYP450 1A2 substrateNon-inhibitor0.5
CYP450 2C9 inhibitorNon-inhibitor0.6234
CYP450 2D6 inhibitorNon-inhibitor0.839
CYP450 2C19 inhibitorNon-inhibitor0.5103
CYP450 3A4 inhibitorNon-inhibitor0.7368
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7691
Ames testNon AMES toxic0.6001
CarcinogenicityNon-carcinogens0.864
BiodegradationNot ready biodegradable0.9938
Rat acute toxicity2.5990 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9916
hERG inhibition (predictor II)Non-inhibitor0.6611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00839 mg/mLALOGPS
logP3.24ALOGPS
logP3.13ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.5ChemAxon
pKa (Strongest Basic)4.26ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area71.78 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity88.89 m3·mol-1ChemAxon
Polarizability34.94 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridines and derivatives. These are compounds containing a pyridine ring, which is a six-member aromatic heterocycle which consists of one nitrogen atom and five carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassNot Available
Direct ParentPyridines and derivatives
Alternative Parents
Substituents
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Oxime ether
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thromboxane-a synthase activity
Specific Function:
Not Available
Gene Name:
TBXAS1
Uniprot ID:
P24557
Molecular Weight:
60517.69 Da
References
  1. Park SJ, Lee JJ, Vanhoutte PM: Endothelin-1 releases endothelium-derived endoperoxides and thromboxane A2 in porcine coronary arteries with regenerated endothelium. Zhongguo Yao Li Xue Bao. 1999 Oct;20(10):872-8. [PubMed:11270983 ]
  2. Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB: Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan;16(1):87-99. [PubMed:11856082 ]
  3. Authors unspecified: Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation. 1994 Feb;89(2):588-95. [PubMed:8313547 ]
  4. De Cree J, Geukens H, Gutwirth P, De Clerck F, Vercammen E, Verhaegen H: The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication. Int Angiol. 1993 Mar;12(1):59-68. [PubMed:8376914 ]
  5. Carty E, Macey M, McCartney SA, Rampton DS: Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2000 Jun;14(6):807-17. [PubMed:10848666 ]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Thromboxane a2 receptor activity
Specific Function:
Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. In the kidney, the binding of TXA2 to glomerular TP receptors causes intense vasoconstriction. Activates phospholipase C. Isoform 1 activates adenylyl cyclase. Isoform 2 inhibits adenylyl ...
Gene Name:
TBXA2R
Uniprot ID:
P21731
Molecular Weight:
37430.69 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Heinisch G, Holzer W, Kunz F, Langer T, Lukavsky P, Pechlaner C, Weissenberger H: On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel. J Med Chem. 1996 Sep 27;39(20):4058-64. [PubMed:8831771 ]
  3. Soyka R, Heckel A, Nickl J, Eisert W, Muller TH, Weisenberger H: 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors. J Med Chem. 1994 Jan 7;37(1):26-39. [PubMed:8289199 ]
  4. Hempelmann RG, Pradel RH, Mehdorn HM, Ziegler A: Threshold concentrations of endothelin-1: the effects on contractions induced by 5-hydroxytryptamine in isolated rat cerebral and mesenteric arteries. Pharmacol Toxicol. 1999 Sep;85(3):115-22. [PubMed:10522750 ]
  5. Carvalho MH, Fortes ZB, Nigro D, Oliveira MA, Scivoletto R: The role of thromboxane A2 in the altered microvascular reactivity in two-kidney, one-clip hypertension. Endothelium. 1997;5(3):167-78. [PubMed:9272380 ]
  6. Ragni M, Golino P, Cirillo P, Pascucci I, Scognamiglio A, Ravera A, Esposito N, Battaglia C, Guarino A, Chiariello M: [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis]. Cardiologia. 1996 Jan;41(1):51-8. [PubMed:8697470 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23